Study Details

Back to Search Results

A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT04451226

Astellas Study ID

The unique identification code given by the study sponsor.

2693-CL-0307

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Hot Flashes

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

40 years - 65 years

Sex

Female

Product

fezolinetant

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jul 2020 - Jun 2022

Masking

None (Open Label)

Enrollment number

150

A Single-Arm Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women in China Suffering from Vasomotor Symptoms (Hot Flashes) Associated with Menopause

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site CN86020

Kunming, China

Site CN86012

Hangzhou, China

Site CN86004

Shenzhen, China

Site CN86024

Fuzhou, China

Site CN86015

Beijing, China

Site CN86032

Chengdu, China

Site CN86025

Wuhan, China

Site CN86042

Guangzhou, China

Site CN86022

Guangzhou, China

Site CN86005

Hunan, China

Site CN86009

Shanghai, China

Site CN86011

Shanxi, China

Site CN86014

Jiangsu, China

Site CN86007

Nanjing, China

Site CN86002

Beijing, China

Site CN86037

Liuzhou, China

Site CN86030

Tianjin, China

Site CN86001

Guangzhou, China

Site CN86006

Nanjing, China

Site CN86026

Suzhou, China

Site CN86018

Nanning, China

Site CN86036

Tianjin, China

Site CN86008

Hangzhou, China

Site CN86010

Jinlin, China

Site CN86029

Beijing, China

Site CN86019

Guangzhou, China

Site CN86028

Shijiazhuang, China

Site CN86027

Lanzhou, China

Site CN86039

Jiangsu, China

Site CN86034

Ningxia Hui Nationality Autonomous Region, China

Site CN86013

Guangxi, China

Site CN86038

Taiyuan, China

Site CN86040

Guangzhou, China

Site CN86023

Guizhou, China

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo